Related Experiment Video
Updated: Apr 25, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
Exploring the Relationship Between Colitis-Associated Cancer and Lipid Metabolism Reprogramming from the Perspective
ShuangShuang Zhang1, Kunshan Li2,3, Dong-Dong Yu4
1Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200030, People's Republic of China.
Aberrant lipid metabolism fuels colitis-associated colorectal cancer (CAC) by altering the tumor microenvironment and immune response. Targeting lipid reprogramming offers new therapeutic strategies for this severe inflammatory bowel disease complication.
Area of Science:
- Oncology
- Gastroenterology
- Metabolic Research
Background:
- Colitis-associated colorectal cancer (CAC) is a severe complication of inflammatory bowel disease (IBD) with poor prognosis.
- Aberrant lipid metabolism is increasingly recognized as a driver of CAC progression.
- Specific metabolic rewiring during chronic colitis leading to malignancy remains underexplored.
Purpose of the Study:
- To dissect the synergistic interactions between lipid metabolism and inflammation, immune microenvironment, and gut dysbiosis in CAC.
- To identify key genes and therapeutic targets in lipid metabolism for CAC.
- To investigate the translational value of targeting lipid metabolic reprogramming in CAC.
Main Methods:
- Systematic review and analysis of current evidence on lipid metabolism in CAC.
- Dissection of the dynamic transition toward malignancy from a metabolic viewpoint.
- Integration of findings on inflammation, immune microenvironment, and intestinal dysbiosis.
Main Results:
- Aberrant lipid metabolism fuels CAC by providing energy, disrupting tumor microenvironment homeostasis, and promoting immune escape.
- A vicious cycle of metabolism-inflammation-carcinogenesis is established.
- Key genes and potential therapeutic targets governing lipid metabolism in CAC have been identified.
Conclusions:
- Lipid reprogramming orchestrates the inflammation-to-cancer shift in CAC.
- Targeting lipid metabolic reprogramming holds translational value for early intervention and combination therapies in CAC.
- Novel research insights and therapeutic strategies can improve clinical prognosis for CAC patients.
More Related Videos
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Ulcerative Colitis
The Tumor Microenvironment
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Cancer Prevention
Some...